



A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation

The Euro Heart Survey

Ron Pisters, MD; Deirdre A. Lane, PhD; Robby Nieuwlaat, PhD; Cees B. de Vos, MD; Harry J. G. M. Crijns, MD; and Gregory Y. H. Lip, MD

Objective: Despite extensive use of oral anticoagulation (OAC) in patients with atrial fibrillation (AF) and the increased bleeding risk associated with such OAC use, no handy quantification tool for assessing this risk exists. We aimed to develop a practical risk score to estimate the 1-year risk for major bleeding (intracranial, hospitalization, hemoglobin decrease >2 g/L, and/or transfusion) in a cohort of real-world patients with AF.

Methods: Based on 3,978 patients in the Euro Heart Survey on AF with complete follow-up, all univariate bleeding risk factors in this cohort were used in a multivariate analysis along with historical bleeding risk factors. A new bleeding risk score termed HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly) was calculated, incorporating risk factors from the derivation cohort.

Results: Fifty-three (1.5%) major bleeds occurred during 1-year follow-up. The annual bleeding rate increased with increasing risk factors. The predictive accuracy in the overall population using significant risk factors in the derivation cohort (C statistic 0.72) was consistent when applied in several subgroups. Application of the new bleeding risk score (HAS-BLED) gave similar C statistics except where patients were receiving antiplatelet agents alone or no antithrombotic therapy, with C statistics of 0.91 and 0.85, respectively.

Conclusion: This simple, novel bleeding risk score (HAS-BLED) provides a practical tool to assess the individual bleeding risk of real-world patients with AF, potentially supporting clinical decision making regarding antithrombotic therapy in patients with AF. *CHEST* 2010; 138(5):1093–1100

Abbreviations: AF = atrial fibrillation; CHADS₂ = congestive heart failure, hypertension, age >75 years, diabetes mellitus, previous stroke/transient ischemic attack (doubled); HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly; HEMOR₂RHAGES = Hepatic or renal disease, Ethanol abuse, Malignancy, Older age (>75 years), Rebleeding, Reduced platelet count or function, Hypertension (uncontrolled), Anemia, Genetic factors, Excessive fall risk, and Stroke; INR = international normalized ratio; OAC = oral anticoagulation

Atrial fibrillation (AF) is associated with a well-known increase in ischemic stroke risk,¹ which is further increased by individual conditions such as heart failure, hypertension, diabetes, and prior thromboembolism.² Oral anticoagulation (OAC) dramatically reduces this risk³ and is therefore recommended in patients with AF at moderate-high risk of stroke and thromboembolism.⁴ The increasing incidence and prevalence of AF increases the likelihood of OAC use in the AF population, which is usually elderly, and comorbidities commonly coexist.⁵⁻⁷ Indeed, clinical

decision making about whether OAC is justified based on stroke risk is supported by various practical stroke risk classification schema that incorporate known clinical risk factors.^{4,8}

For editorial comment see page 1032

However, stroke risk is also closely related to bleeding risk,⁹ and OAC prescription needs to balance the benefit from stroke prevention against the risk of bleeding. Thus, there is often suboptimal

implementation of thromboprophylaxis among patients with AF,^{9,10} which may be partly due to the lack of a validated bleeding risk-stratification schema that is user-friendly.¹¹⁻¹³ This is further reflected by the absence of recommendations on bleeding risk assessment in current antithrombotic guidelines for AF management.^{4,12} The available schemas estimating the risk of bleeding associated with use of OAC either do not focus on patients with AF in particular,^{14,15} address a (very) specific subgroup among patients with AF,¹⁶ or incorporate routinely unavailable risk factors that also overlap significantly with stroke risk factors.¹⁷ Furthermore, all published schema are based on historical cohorts of patients and consequently may not reflect advancements in medical care over time (for example, OAC monitoring) and treatment of underlying heart disease.¹⁴⁻¹⁷ Our aim was to develop a practical risk score to estimate the 1-year risk of major bleeding (intracranial, hospitalization, hemoglobin decrease > 2 g/L, and/or transfusion) in a contemporary, real-world cohort of patients with AF.

MATERIALS AND METHODS

We used the large population database of the prospective Euro Heart Survey on AF, with data collected between 2003 and 2004. A detailed study outline of the Euro Heart Survey on AF at baseline⁵ and follow-up assessment¹⁸ has been previously described. In summary, 5,333 ambulatory and hospitalized patients with AF from 182 university, nonuniversity, and specialized hospitals among 35 member countries of the European Society of Cardiology were enrolled. Patients had to be ≥ 18 years of age and have an ECG or Holter-proven diagnosis of AF during the qualifying admission or in the preceding year. A 1-year follow-up assessment was performed to determine survival and major adverse cardiovascular events, such as major bleeding. Medical records and/or medical information systems were used to populate the data set.

We defined major bleeding as any bleeding requiring hospitalization and/or causing a decrease in hemoglobin level of > 2 g/L and/or requiring blood transfusion that was not a hemorrhagic

stroke. Hemorrhagic stroke was defined as a focal neurologic deficit of sudden onset, diagnosed by a neurologist, lasting > 24 h and caused by bleeding. Presence of chronic dialysis, renal transplantation, or serum creatinine ≥ 200 $\mu\text{mol/L}$ was classified as abnormal kidney function. Abnormal liver function was defined as chronic hepatic disease (eg, cirrhosis) or biochemical evidence of significant hepatic derangement (eg, bilirubin > 2 \times upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase > 3 \times upper limit normal, and so forth). Finally, valvular heart disease was defined as the presence of any regurgitation or gradient over a valve with hemodynamic significance and/or related symptoms.

Statistical Analysis and Design of a New Bleeding Risk Score

Data analysis was performed with SPSS, version 16.0 (SPSS Inc., Chicago, IL). The presence of any differences between the groups with and without major bleeding during 1-year follow-up was tested by Fisher exact test for categorical variables and by independent samples *t* test for continuous variables.

All potential bleeding risk factors identified from the univariate analyses of the derivation cohort with a *P* value < .10 (age > 65 years, female sex, diabetes mellitus, heart failure, COPD, valvular heart disease, kidney failure, prior major bleeding episode, and clopidogrel use), were used in the multivariate logistic regression analyses along with more historical bleeding risk factors: OAC, alcohol use, and hypertension. We disregarded thyroid disease (*P* = .039) because of difficulties with interpretation (only *n* = 10 bleeding events), and this had not been identified as a bleeding risk in prior systematic reviews.¹¹⁻¹³ Given the persistent nature of the evidence of OAC, hypertension, age > 65 years, renal failure, alcohol abuse, and prior major bleed as bleeding risk factors, these variables were kept in the model at all times. The other, less strongly linked variables were removed stepwise from the model when the *P* value was > .10. Variables with *P* < .05 in the final model were considered to be significant contributors and were checked for interaction effects, which did not exist.

In recognition of the limited number of major bleeds and relatively short follow-up period in the Euro Heart Survey on AF, we also added consistent risk factors for major bleeding (stroke, alcohol use, systolic BP > 160 mm Hg, and so forth) identified in recent systematic reviews^{11,13} to use the data from the derivation cohort to test a new bleeding risk score in a final statistical model, accepting the lack of statistical significance of some variables in our derivation cohort. For each of the variables in the final model the regression coefficient, net OR, and its 95% CI and *P* value are reported (Table 1). We then calculated the C statistic as a measure of the predictive accuracy of the model incorporating bleeding risk factors from the derivation cohort (that is, prior major bleeding, age > 65 years, clopidogrel use, and kidney failure), where, based on their respective multivariate regression coefficients, two points were awarded for prior major bleeding and one point for each of the other bleeding risk factors. In addition, we report the C statistics in a subgroup analysis of individuals discharged with OAC monotherapy, OAC combined with an antiplatelet drug, an antiplatelet drug alone, or no antithrombotic therapy.

A new bleeding risk score (termed HAS-BLED) was calculated, incorporating risk factors from the derivation cohort as well as significant risk factors for major bleeding found in the literature from systematic reviews.^{11,13} HAS-BLED is an acronym for hypertension (uncontrolled, > 160 mm Hg systolic), abnormal renal/liver function (one point for presence of renal or liver impairment, maximum two points), stroke (previous history, particularly lacunar), bleeding history or predisposition (anemia), labile international normalized ratio (INR) (ie, therapeutic time in range < 60%), elderly (> 65 years), drugs/alcohol concomitantly (antiplatelet

Manuscript received January 17, 2010; revision accepted March 1, 2010.

Affiliations: From the Department of Cardiology (Drs Pisters, Nieuwlaat, de Vos, and Crijns), Maastricht University Medical Centre, Maastricht, The Netherlands; and the University of Birmingham Centre for Cardiovascular Sciences (Drs Lane and Lip), City Hospital, Birmingham, England.

Funding/Support: The Euro Heart Survey has as industry sponsors the main sponsor, AstraZeneca; major sponsor, Sanofi-Aventis; and sponsor, Eucomed. Funding institutions are the Austrian Heart Foundation, Austrian Society of Cardiology, French Federation of Cardiology, Hellenic Cardiological Society, Netherlands Heart Foundation, Portuguese Society of Cardiology, Spanish Cardiac Society, Swedish Heart and Lung Foundation, and individual centers.

Correspondence to: Gregory Y. H. Lip, MD, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, England; e-mail: g.y.h.lip@bham.ac.uk

© 2010 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (<http://www.chestpubs.org/site/misc/reprints.xhtml>).

DOI: 10.1378/chest.10-0134

Table 1—Clinical Risk Factors for Major Bleeding Within 1 Year in Patients With Atrial Fibrillation Enrolled in the Euro Heart Survey

Risk Factor	MV Regression Coefficient	Event Rate With Risk Factor	Event Rate Without Risk Factor	Univariate P Value	OR (95% CI)	MV P Value
Systolic BP > 160 mm Hg	-0.52	4 (1.0)	11 (1.4)	.515	0.60 (0.21-1.72)	.337
Kidney failure	1.05	10 (5.4)	43 (1.3)	< .001	2.86 (1.33-6.18)	.007
Stroke	-0.44	4 (2.1)	48 (1.5)	.532	0.94 (0.32-2.86)	.940
Prior major bleeding	2.02	9 (14.8)	44 (1.3)	< .001	7.51 (3.00-18.78)	< .001
Age > 65 y	0.98	42 (2.3)	11 (0.7)	< .001	2.66 (1.33-5.32)	.007
Antiplatelet agent ^a	-0.22	5 (3.4)	46 (1.4)	.066	0.81 (0.43-1.51)	.504
Alcohol use ^b	-16.80	10 (1.6)	31 (1.9)	1.000	0.00 (0.00)	.996

MV = multivariate.

^aAspirin or clopidogrel.

^b> 8 U/wk.

agents, nonsteroidal antiinflammatory drugs; one point for drugs plus one point for alcohol excess, maximum two points) as shown in Table 2.

In order to compare the predictive accuracy of our novel bleed risk score (HAS-BLED) with the previously proposed HEMOR₂RHAGES (Hepatic or renal disease, Ethanol abuse, Malignancy, Older age [> 75 years], Rebleeding, Reduced platelet count or function, Hypertension [uncontrolled], Anemia, Genetic factors, Excessive fall risk, and Stroke) scheme, patients were classified accordingly¹⁷; however, we considered “uncontrolled hypertension” to be > 160 mm Hg systolic, a “history of malignancy” to be similar to “current malignancy,” and we classified ≥ 8 units alcoholic consumption per week as “ethanol abuse.” Relevant genetic and laboratory data (required for calculation of the HEMOR₂RHAGES schema), apart from serum creatinine, were not available for the Euro Heart Survey on AF cohort.

RESULTS

Of the 5,272 patients with AF in the Euro Heart Survey of AF who were discharged alive,⁵ 3,456 (66%) patients without mitral valve stenosis or valvular surgery had 1-year follow-up status regarding major bleeding. The overall mean (SD) age was 66.8 (12.8) years, and the majority were men (59%). Fifty-three (1.5%) patients experienced a major bleed during the first year, including nine (17%) cases of intracerebral

Table 2—Clinical Characteristics Composing the HAS-BLED Bleeding Risk Score

Letter	Clinical Characteristic ^a	Points Awarded
H	Hypertension	1
A	Abnormal renal and liver function (1 point each)	1 or 2
S	Stroke	1
B	Bleeding	1
L	Labile INRs	1
E	Elderly	1
D	Drugs or alcohol (1 point each)	1 or 2

HAS-BLED = Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (> 65 years), Drugs/alcohol concomitantly; INR = international normalized ratio.

^aSee “Materials and Methods” for definitions of the clinical characteristics.

hemorrhage. The baseline demographic and clinical characteristics of the 3,456 patients are presented in Table 3.

Of all discharged patients, 2,242 (64.8%) were on OAC (286 [12.8%] of whom also received aspirin and/or clopidogrel), 828 (24.0%) received antiplatelet therapy alone (aspirin and/or clopidogrel), and 352 (10.2%) received no antithrombotic therapy. The distribution of the risk factors for major bleeding within 1 year among the different antithrombotic treatment regimens in the derivation cohort is depicted

Table 3—Baseline Characteristics of Patients With Atrial Fibrillation From the Euro Heart Survey With a Known Follow-up Status Regarding Major Bleeding

Characteristic	Bleed (n = 53)	No Bleed (n = 3,910)	P Value
Age, mean (SD), y	73 (10)	66 (13)	< .001
Age > 65 y	42 (79)	1,748 (51)	< .001
Female sex	28 (53)	1,329 (39)	.046
BMI, mean (SD), kg/m ²	27 (5)	28 (8)	.298
Atrial fibrillation type			.827
First detected	9 (17)	628 (19)	
Paroxysmal	15 (28)	1,029 (31)	
Persistent/permanent	29 (56)	1,688 (51)	
Medical history			
Current smoker	6 (11)	450 (13)	.716
Hypertension	39 (74)	2,228 (65)	.245
Diabetes mellitus	12 (23)	610 (18)	.367
Coronary artery disease	15 (29)	1,182 (35)	.462
Heart failure	24 (45)	994 (24)	.014
Valvular heart disease	18 (34)	607 (18)	.006
COPD	12 (23)	427 (13)	.037
Thyroid disease	10 (20)	326 (10)	.059
Stroke/transient ischemic attack	6 (12)	355 (11)	.818
CHADS ₂ score, mean (SD)	2.07 (1.16)	1.60 (1.27)	.008
Bleeding risk factors			
Prior major bleed	9 (17)	52 (2)	< .001
Systolic BP, mean (SD)	137(20)	136 (22)	.856
Malignancy	4 (8)	183 (5)	.529
Renal failure	10 (19)	174 (5)	< .001
Alcohol use ≥ 8 U/wk	0 (0)	170 (5)	.111

Values presented are No. (%) unless otherwise indicated. CHADS₂ = congestive heart failure, hypertension, age > 75 , diabetes mellitus, and previous stroke/transient ischemic attack (doubled).

in Table 4. The risk of major bleeding within 1 year in patients with AF in the Euro Heart Survey determined by the novel bleeding risk score, HAS-BLED, is shown in Table 5. The annual bleeding rate increased with the addition of each risk factor from the derivation cohort (Table 5).

The corresponding unadjusted bleeding rates in patients with OAC, antiplatelet therapy alone, or no antithrombotic treatment were 1.75, 0.97, and 1.42 bleeds per 100 patient-years, respectively. The predictive accuracy in the overall population using significant risk factors in the derivation cohort (C statistic 0.72) was consistent when applied in several subgroups, as shown in Table 6. Application of the new bleeding risk score (HAS-BLED) gave similar C statistics to that derived in the derivation cohort overall (0.72), or when patients were established on OAC at baseline (0.69), or when patients were on OAC plus antiplatelet therapy at baseline (0.78). HAS-BLED substantially improved the predictive accuracy of bleeding risk when patients with AF were receiving antiplatelet therapy alone or in those who were not on antithrombotic therapy at all (with C statistics of 0.91 and 0.85, respectively). The HEMOR₂RHAGES bleeding scheme had a lower predictive accuracy compared with the new HAS-BLED score, overall or in relation to antithrombotic therapy use, except in the OAC plus antiplatelet therapy subgroup (Table 6).

Of all the 33 bleeding events in patients discharged with OAC because of a CHADS₂ (congestive heart failure, hypertension, age > 75 years, diabetes mellitus, and previous stroke/transient ischemic attack [doubled]) score ≥ 1 , four (12%) patients had a HAS-BLED-based bleeding risk that outweighed their individual stroke risk. Conversely, of all 1,580 patients discharged with OAC because of a CHADS₂ score ≥ 1 who did not suffer a major bleed within 1 year, only 34 (2.2%) had a HAS-BLED-based bleeding risk that outweighed their individual stroke risk. Of all

21 patients with a CHADS₂ score ≥ 1 discharged without OAC who suffered a stroke within 1 year of follow-up, only one had a HAS-BLED score outweighing the individual stroke risk. Of the patients with CHADS₂ score ≥ 1 who were discharged without OAC with a higher HAS-BLED bleeding risk score, all three patients suffered a major bleed.

DISCUSSION

Using a derivation cohort based on the large, real-world population of the Euro Heart Survey on AF, we identified four independent risk factors of major bleeding within 1 year (prior major bleeding, age > 65 years, clopidogrel use, and kidney failure). Incorporating these risk factors with other established risk factors from systematic reviews and multivariate analyses,^{11,13,19} we developed and tested a novel, user-friendly bleeding risk score, HAS-BLED, which demonstrated a good predictive accuracy in the overall Euro Heart survey cohort (C statistic 0.72) but performed particularly well in predicting bleeding risk where antiplatelet therapy was used alone (C statistic 0.91), or no antithrombotic therapy at all (C statistic 0.85). Assessment of both stroke and bleed risk using the CHADS₂ and HAS-BLED schemas, respectively, in the Euro Heart Survey on AF population would have resulted in withholding OAC therapy in 12% of the patients who suffered a major bleed within 1 year and the initiation of OAC in 95% of the patients at high risk for stroke who were discharged without OAC and had suffered a stroke within 1 year.

With the previously published HEMOR₂RHAGES schema¹⁷ and others,^{11,19} the concept of a risk score for major bleeding in patients with AF is not new. However, our novel, proposed HAS-BLED score has several key advantages over the previously mentioned bleeding risk stratification method. First, the shorter acronym means that physicians have fewer risk factors to memorize when using the HAS-BLED score, thereby increasing the user-friendliness and subsequent clinical application. Furthermore, in contrast to certain risk factors incorporated into the HEMOR₂RHAGES score that require laboratory parameters or even genetic testing,¹⁷ all risk factors of the HAS-BLED score are either readily available from the clinical medical history or routinely tested in (new) patients with AF. This characteristic strongly supports its use in all health-care settings and is another significant contributor to its superior user-friendliness. Because less does not necessarily mean more, it is important to note that the predictive accuracy of the HAS-BLED score is broadly similar when compared with the HEMOR₂RHAGES model in the overall population (C statistic of 0.72 vs 0.66,

Table 4—Clinical Risk Factors for Major Bleeding Within 1 Year in Patients With Atrial Fibrillation of the Euro Heart Survey According to Antithrombotic Treatment at Discharge

Bleeding Risk Factor	Oral Anticoagulation (n = 2,115)	Aspirin/ Clopidogrel (n = 828)	Neither (n = 352)
Systolic BP > 160 mm Hg	10.0	13.4	13.7
Kidney failure	5.3	4.8	6.8
Stroke	5.9	5.0	3.2
Prior major bleeding	1.7	1.6	3.2
Age > 65 y	53.3	52.8	42.6
Antiplatelet agent	12.1	100	0.0
Alcohol use ^a	5.7	4.8	5.0

Data shown as percentages.

^a ≥ 8 U/wk.

Table 5—The Risk of Major Bleeding Within 1 Year in Patients With Atrial Fibrillation Enrolled in the Euro Heart Survey

Risk Factors/Score	Derivation Cohort ^a			HAS-BLED		
	No.	No. of Bleeds	Bleeds Per 100 Patient-Years	No.	No. of Bleeds	Bleeds Per 100 Patient-Years
0	1,517	9	0.59	798	9	1.13
1	1,589	24	1.51	1,286	13	1.02
2	219	7	3.20	744	14	1.88
3	41	8	19.51	187	7	3.74
4	14	3	21.43	46	4	8.70
5	1	0	...	8	1	12.50
6	2	0	0.0
7	0
8	0
9	0
Any score	3,381	51	1.51	3,071	48	1.56
<i>P</i> value for trend			<0.001			0.007

See Table 2 for expansion of abbreviations.

^aDerivation cohort risk factors in multivariate analysis: bleeding history (given 2 points), age > 65 y, clopidogrel use, and kidney failure (maximum score 5).

respectively).¹⁷ However, the HAS-BLED score was particularly useful when antiplatelet therapy was used alone or no antithrombotic therapy was used at all (C statistics of 0.91 and 0.85, respectively). Although the HAS-BLED score and the HEMOR₂RHAGES model were broadly similar in subjects who were not taking antithrombotic therapy at baseline (C statistics

Table 6—Predictive Power of the Bleeding Risk Scores Used To Assess Risk of Major Bleeding Within 1 Year in Patients With Atrial Fibrillation

Antithrombotic Treatment	Bleeding Risk Score	No.	C Statistic (CI)
Overall group	Derivation cohort ^a	3,381	0.72 (0.64-0.79)
	HAS-BLED	3,071	0.72 (0.65-0.79)
	HEMOR ₂ RHAGES ^b	3,040	0.66 (0.57-0.74)
OAC alone	Derivation cohort	1,947	0.68 (0.58-0.78)
	HAS-BLED	1,722	0.69 (0.59-0.80)
	HEMOR ₂ RHAGES	1,706	0.64 (0.53-0.75)
OAC + antiplatelet therapy	Derivation cohort	240	0.80 (0.68-0.93)
	HAS-BLED	239	0.78 (0.65-0.91)
	HEMOR ₂ RHAGES	235	0.83 (0.74-0.91)
Antiplatelet therapy alone	Derivation cohort	788	0.74 (0.52-0.97)
	HAS-BLED	753	0.91 (0.83-1.00)
	HEMOR ₂ RHAGES	728	0.83 (0.68-0.98)
No antithrombotic therapy	Derivation cohort	348	0.75 (0.51-0.99)
	HAS-BLED	315	0.85 (0.00-1.00)
	HEMOR ₂ RHAGES	311	0.81 (0.00-1.00)

HEMOR₂RHAGES = Hepatic or renal disease, Ethanol abuse, Malignancy, Older age (> 75 years), Rebleeding, Reduced platelet count or function, Hypertension (uncontrolled), Anemia, Genetic factors, Excessive fall risk, and Stroke; OAC = oral anticoagulation. See Table 2 for expansion of other abbreviation.

^aDerivation cohort risk factors: bleeding history, age > 65 y, clopidogrel use, and kidney failure.

^bClassifying bleeding risk by antithrombotic therapy use with the HEMOR₂RHAGES scheme resulted in mean scores of 1.17, 1.17, 1.31, 1.24, and 1.07, respectively.

of 0.85 vs 0.81, respectively), the HAS-BLED score is simpler. This score would be particularly useful in everyday clinical practice, when making decisions on whether OAC can be initiated in a patient newly diagnosed with AF who is not taking any antithrombotic therapy,¹² or when antiplatelet therapy (or Nonsteroidal antiinflammatory drugs) use is being considered, for example, in the setting of coronary artery disease.²⁰

As mentioned previously, balancing the individual risk of bleeding and stroke is difficult²¹ but of the utmost importance to maximize appropriate antithrombotic therapy and minimize adverse events in patients with AF, resulting in a net clinical benefit for the treated patient. In daily clinical practice, the CHADS₂ index⁸ is a widely used tool to stratify stroke risk in patients with AF. For now, the HEMOR₂RHAGES score is the only suitable counterpart available to assess the risk of bleeding in AF patients.¹⁷ Closer examination of the risk factors composing the CHADS₂ and HEMOR₂RHAGES schemas reveals an extensive overlap between risk factors for bleeding and stroke, which has obvious drawbacks.^{8,17} Indeed, the patients at highest stroke and thromboembolic risk are paradoxically more likely to sustain bleeding complications. This may lead to confusion when trying to decide on the most appropriate antithrombotic regimen to balance the risks of bleeding against the risk of stroke, thereby limiting the applicability of such schemas.

The trade-off in terms of the benefits and risks of OAC using the CHADS₂ index and HAS-BLED score demonstrates that in the vast majority of patients with AF who require OAC (CHADS₂ index ≥ 2) the risk of bleeding outweighs the potential benefit of OAC if the HAS-BLED bleed score exceeds the individual CHADS₂ index. In the case of a CHADS₂ score of 1, the HAS-BLED score must exceed 2 for the potential harm caused by OAC to offset its beneficial effect

on stroke risk reduction. Appropriate use of this practical rule in the Euro Heart Survey on AF population could have prevented more than one out of every 10 (4/33) of the major bleeds. However, 34/1,580 (2.2%) of the patients with a CHADS₂ score \geq 1 discharged with OAC who did not suffer a major bleed within 1 year would have been denied OAC because of a HAS-BLED bleed risk outweighing their stroke risk.

The potential impact on current clinical practice of the novel HAS-BLED score is underlined by the recently published Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events-A (ACTIVE-A) trial.²² This large randomized clinical trial was designed to compare the preventive effect on all-cause vascular events of clopidogrel plus aspirin vs aspirin alone in patients with AF deemed unsuitable for OAC treatment. In half ($n \sim 3,500$) of these patients with AF with a high stroke risk, the most common applied classification was “unsuitable for OAC,” which was solely based on physician clinical judgment, without the presence of any predefined risk factor of bleeding or other objective risk scoring. Perhaps this reflects physicians’ uncertainty about what to consider as true risk factors of bleeding and their fear of potential iatrogenic harm caused by OAC use.

Given the recent promising results of the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial,²³ patients assessed as being at higher bleeding risk using the novel HAS-BLED score could be prescribed the lower dose (110 mg bid) of the oral direct thrombin inhibitor, dabigatran, which demonstrated a significant reduction in major bleeding compared with warfarin, with a similar stroke risk reduction to warfarin, whereas those at lower bleeding risk could be prescribed dabigatran 150 mg bid, which offers superior efficacy but a similar major bleeding risk to warfarin.²⁴ Further, the HAS-BLED score could also be used to identify patients who may benefit from a left atrial appendage occlusion device²⁵ (ie, patients at high risk of ischemic stroke who have such an increased risk of bleeding that OAC is contraindicated). Thus, physicians initiating OAC (whether with the vitamin K antagonist or new oral anticoagulants, such as dabigatran) in a patient with AF could use the HAS-BLED score to assess the potential bleeding risk and feel more confident in prescribing OAC as appropriate or refer the patient for implantation of a left atrial appendage occlusion device. Indeed, bleeding risk scores should also be validated in dabigatran-treated patients, as well as those being considered for left atrial appendage occlusion devices.

Limitations

The HAS-BLED score needs to be validated in at least one other large contemporary cohort of patients

with AF before it can be widely implemented into daily practice. Potential selection bias might have occurred because of 25% missing data regarding the occurrence of major bleeding during the follow-up period. Patients who were lost to follow-up were likely to have had more comorbidities and transferred to nursing homes or even have died, which might have led to underestimation of the overall bleeding rate. Also, we recognize that the limited number of major bleeds and the relatively short follow-up period make it possible that other important risk factors for bleeding were not identified. Indeed, bleeding may occur following changes to warfarin (eg, for surgery or interventions such as pacemaker implant) with institution of bridging therapy with low-molecular heparin. We also did not consider thyroid disease in our model, as this had not been identified as a bleeding risk in prior systematic reviews¹¹⁻¹³; however, some pathophysiologic plausibility is possible, since hypothyroidism has been described to cause acquired von Willebrand disease associated with low factor VIII levels and platelet dysfunction.²⁶ Of note, there is an improved predictive power of the HAS-BLED score over the HEMOR₂-RHAGES score in patients treated with antiplatelet therapy (or nonsteroidal antiinflammatory drugs) or no antithrombotic therapy at all (Table 6).

The risk of major bleeding (especially intracranial hemorrhage) is increased with advanced age.²⁶⁻²⁸ Of note, the risk of major hemorrhage can be similar among elderly patients receiving warfarin and aspirin.²⁹ The relatively small numbers of bleeding events and the modest number of very elderly patients in our cohort makes it rather difficult to draw too many firm conclusions by introducing different weights to different age categories (eg, one point for age 65-74 years, two points for age 75-84 years, three points for age \geq 85 years, and so forth), as well as introducing additional complexity to our simple HAS-BLED scoring system. Also, age is a continuous (rather than categorized) risk for bleeding (as well as stroke) and the biologic age of an elderly patient is probably more relevant to bleeding risk than the chronologic age. It must be stressed that in many instances, bleeding risk among the elderly is multifactorial³⁰ and is often the result of associated comorbidities, high anticoagulation intensity, and labile INRs in this population.¹¹⁻¹³ The HAS-BLED score already takes some of these aspects into account, allowing cumulative assessment of risk factors for bleeding. In the present analysis, the HAS-BLED score already outperforms the HEMOR₂RHAGES bleeding scheme, which was an attempt by Gage et al¹⁷ to have a simple method of bleeding assessment. Future validation and refinement of HAS-BLED among a huge elderly AF population with prolonged follow-up may address the issue of age as a continuous variable for bleeding risk.

Finally, data about INR control are obviously not available when having to decide on starting OAC for the first time in a patient. When on OAC, the INR is often elevated at the time of admission for a bleeding event, but it is unknown which measure of INR control best predicts bleeding in such a manner that clinical action could prevent the bleeding. We did not include actual INR values during follow-up but acknowledge its importance as risk factor of bleeding.¹⁹ Of note, the current alternative (HEMOR₂RHAGES model) was also developed without the availability of INR values.¹⁷

CONCLUSION

We propose a novel bleeding risk score, HAS-BLED, that provides an easy, practical tool to assess the individual bleeding risk of patients with AF. The use of this simple score may potentially support clinical decision making regarding antithrombotic therapy for stroke prevention.

ACKNOWLEDGMENTS

Author contributions: *Dr Pisters:* contributed to statistical analyses, data interpretation, and drafting of the manuscript.

Dr Lane: contributed to drafting and revision of the manuscript.

Dr Nieuwlaat: contributed to statistical analyses, data interpretation, and drafting of the manuscript.

Dr de Vos: contributed to drafting and revision of the manuscript.

Dr Crijns: contributed to drafting and revision of the manuscript.

Dr Lip: contributed to study design and hypothesis, concept of the HAS-BLED score (the Birmingham Atrial Fibrillation Bleeding Risk schema), data interpretation, drafting of manuscript, and revisions.

Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Pisters has consulting fees from Bayer and Boehringer Ingelheim and lecture fees from Boehringer Ingelheim. Dr Lane is the recipient of an investigator-initiated educational grant from Bayer Healthcare and has received sponsorship to attend the European Society of Cardiology Congress 2009 from AstraZeneca. Dr Crijns has received consulting fees from Boehringer Ingelheim, Sanofi-Aventis, and AstraZeneca; grant support from St. Jude Medical, Boston Scientific, Boehringer Ingelheim, Sanofi-Aventis, Medapharma, and Merck; and honoraria from Medtronic, Sanofi-Aventis, Medapharma, Merck, Boehringer Ingelheim, and Biosense Webster. Dr Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi-Aventis, Aryx, Portola, Biotronic, and Boehringer Ingelheim, and has been on the speakers bureau for Bayer, Boehringer Ingelheim, and Sanofi-Aventis. Drs Nieuwlaat and de Vos have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Other contributions: We thank the Euro Heart Survey team, national coordinators, investigators, and data collection officers for performing the survey.

REFERENCES

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991;22(8):983-988.

2. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994;154(13):1449-1457.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146(12):857-867.
4. Fuster V, Rydén LE, Cannom DS, et al; European Heart Rhythm Association; Heart Rhythm Society; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). *J Am Coll Cardiol*. 2006;48(4):854-906.
5. Nieuwlaat R, Capucci A, Camm AJ, et al; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J*. 2005;26(22):2422-2434.
6. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J*. 2006;27(8):949-953.
7. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation*. 2006;114(2):119-125.
8. Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA*. 2001;285(22):2864-2870.
9. Nieuwlaat R, Capucci A, Lip GY, et al; Euro Heart Survey Investigators. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J*. 2006;27(24):3018-3026.
10. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. *J Am Coll Cardiol*. 2005;46(9):1729-1736.
11. Palareti G, Cosmi B. Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. *Thromb Haemost*. 2009;102(2):268-278.
12. National Collaborating Centre for Chronic Conditions. *Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care*. London, England: Royal College of Physicians.
13. Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. *QJM*. 2007;100(10):599-607.
14. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *Am J Med*. 1998;105(2):91-99.
15. Kuijler PM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. *Arch Intern Med*. 1999;159(5):457-460.
16. Shireman TI, Howard PA, Kresowik TF, Ellerbeck EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. *Stroke*. 2004;35(10):2362-2367.

17. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). *Am Heart J*. 2006;151(3):713-719.
18. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. *Eur Heart J*. 2008;29(9):1181-1189.
19. Tay KH, Lane DA, Lip GY. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel any safer than aspirin when combined with warfarin? *Thromb Haemost*. 2008;100(6):955-957.
20. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. *Thromb Haemost*. 2010;103(1):13-28.
21. Lip GY, Zarifis J, Watson RD, Beevers DG. Physician variation in the management of patients with atrial fibrillation. *Heart*. 1996;75(2):200-205.
22. Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*. 2009;360(20):2066-2078.
23. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361(12):1139-1151.
24. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH; The National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. *Ann Intern Med*. 1996;124(11):970-979.
25. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet*. 2009;374(9689):534-542.
26. Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. *J Clin Endocrinol Metab*. 2007;92(8):3006-3012.
27. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. *Ann Intern Med*. 2004;141(10):745-752.
28. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. *Stroke*. 2009;40(4):1410-1416.
29. Mant J, Hobbs FDR, Fletcher K, et al; BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet*. 2007;370(9586):493-503.
30. Arboix A, Vall-Llosera A, García-Eroles L, Massons J, Oliveres M, Targa C. Clinical features and functional outcome of intracerebral hemorrhage in patients aged 85 and older. *J Am Geriatr Soc*. 2002;50(3):449-454.